|Grant Number:||5U01CA078527-15 Interpret this number|
|Primary Investigator:||Burk, Robert|
|Organization:||Albert Einstein College Of Medicine|
|Project Title:||Persistent HPV in Women at Risk for Cervix Cancer|
DESCRIPTION (provided by applicant): We are now in an era of an FDA approved prophylactic HPV16/18 vaccine for the two major types of HPV causing cervix cancer. Nevertheless, there are many critical questions about the natural history of non-HPV16/18 HPV types associated with cervix cancer and the fine specificity of the vaccine that remain and need to be addressed. The central hypothesis of this application is that DNA mutation and natural selection have driven the evolution of success amongst HPV infections resulting also in the emergence of cancer causing viruses, as a byproduct of filling a specific biological niche. We will utilize epidemiological methods and the analytic tools of evolution and systems biology to study the role of oncogenic HPV types and variants in population-based studies of HPV natural history and cervix neoplasia. We propose 3 specific aims: (1) To define the natural history of the a7 (18-related) and a9 (16-related) HPV types in the HPV Persistence and Progression (PaP) Cohort at Kaiser Permanente Northern California, a new cohort study of 35,000 HR-HPV positive (HC2+) women z 30 yrs of age women and in the 21,000 women from the Portland study with 16 years of follow-up; (2) To determine vaccine efficacy for HPV16/18-variants and related type variants after vaccination with HPV16/18 VLPs in the Costa Rica Vaccine Trial (CVT), a phase III HPV 16/18 vaccine trial of 7500 women 18-25 years of age in Guanacaste; and (3) To identify the genetic basis for the oncogenicity of high-risk HPV types and variants. There is a gradient of oncogenic risk from the most oncogenic, HPV16, to less oncogenic types (e.g., HPV31/35/45/56) to non-oncogenic (e.g., HPV53/70) HPV types within the "oncogenic" species groups a.5-7, a9 and a11. We will infer full viral genome sequence from variant "haplotype" information. This data will be combined with pathologic state and/or case-control status from the results generated in the cohort studies to determine genotype-phenotype relationships using a variety of phylogenetic and analytic approaches. Overall the data will provide important information on phenotypic-genetic relationships.
Lactobacillus crispatus dominant vaginal microbiome is associated with inhibitory activity of female genital tract secretions against Escherichia coli.
Authors: Ghartey JP, Smith BC, Chen Z, Buckley N, Lo Y, Ratner AJ, Herold BC, Burk RD
Source: PLoS One, 2014;9(5), p. e96659.
EPub date: 2014 May 7.
Human papillomavirus 33 worldwide genetic variation and associated risk of cervical cancer.
Authors: Chen AA, Heideman DA, Boon D, Chen Z, Burk RD, De Vuyst H, Gheit T, Snijders PJ, Tommasino M, Franceschi S, Clifford GM
Source: Virology, 2014 Jan 5;448, p. 356-62.
EPub date: 2013 Nov 12.
Human papillomavirus genome variants.
Authors: Burk RD, Harari A, Chen Z
Source: Virology, 2013 Oct;445(1-2), p. 232-43.
EPub date: 2013 Aug 31.
Evolution and taxonomic classification of alphapapillomavirus 7 complete genomes: HPV18, HPV39, HPV45, HPV59, HPV68 and HPV70.
Authors: Chen Z, Schiffman M, Herrero R, DeSalle R, Anastos K, Segondy M, Sahasrabuddhe VV, Gravitt PE, Hsing AW, Burk RD
Source: PLoS One, 2013;8(8), p. e72565.
EPub date: 2013 Aug 16.
Oral human papillomavirus detection in older adults who have human immunodeficiency virus infection.
Authors: Fatahzadeh M, Schlecht NF, Chen Z, Bottalico D, McKinney S, Ostoloza J, Dunne A, Burk RD
Source: Oral Surg Oral Med Oral Pathol Oral Radiol, 2013 Apr;115(4), p. 505-14.
EPub date: 2013 Jan 31.
Association between hTERT activation by HPV E6 proteins and oncogenic risk.
Authors: Van Doorslaer K, Burk RD
Source: Virology, 2012 Nov 10;433(1), p. 216-9.
EPub date: 2012 Aug 25.
The cervical microbiome over 7 years and a comparison of methodologies for its characterization.
Authors: Smith BC, McAndrew T, Chen Z, Harari A, Barris DM, Viswanathan S, Rodriguez AC, Castle P, Herrero R, Schiffman M, Burk RD
Source: PLoS One, 2012;7(7), p. e40425.
EPub date: 2012 Jul 9.
Characterization of human papillomavirus type 120: a novel betapapillomavirus with tropism for multiple anatomical niches.
Authors: Bottalico D, Chen Z, Kocjan BJ, Seme K, Poljak M, Burk RD
Source: J Gen Virol, 2012 Aug;93(Pt 8), p. 1774-9.
EPub date: 2012 May 2.
Effectiveness of a simple rapid human papillomavirus DNA test in rural Nigeria.
Authors: Gage JC, Ajenifuja KO, Wentzensen N, Adepiti AC, Stoler M, Eder PS, Bell L, Shrestha N, Eklund C, Reilly M, Hutchinson M, Wacholder S, Castle PE, Burk RD, Schiffman M
Source: Int J Cancer, 2012 Dec 15;131(12), p. 2903-9.
EPub date: 2012 Apr 27.
A large, population-based study of age-related associations between vaginal pH and human papillomavirus infection.
Authors: Clarke MA, Rodriguez AC, Gage JC, Herrero R, Hildesheim A, Wacholder S, Burk R, Schiffman M
Source: BMC Infect Dis, 2012 Feb 8;12, p. 33.
EPub date: 2012 Feb 8.
Classification and nomenclature system for human Alphapapillomavirus variants: general features, nucleotide landmarks and assignment of HPV6 and HPV11 isolates to variant lineages.
Authors: Burk RD, Chen Z, Harari A, Smith BC, Kocjan BJ, Maver PJ, Poljak M
Source: Acta Dermatovenerol Alp Pannonica Adriat, 2011 Sep;20(3), p. 113-23.
The oral cavity contains abundant known and novel human papillomaviruses from the Betapapillomavirus and Gammapapillomavirus genera.
Authors: Bottalico D, Chen Z, Dunne A, Ostoloza J, McKinney S, Sun C, Schlecht NF, Fatahzadeh M, Herrero R, Schiffman M, Burk RD
Source: J Infect Dis, 2011 Sep 1;204(5), p. 787-92.
Long-term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment.
Authors: Kreimer AR, Schiffman M, Herrero R, Hildesheim A, González P, Burk RD, Porras C, Sherman ME, Demuth F, Cheung L, Bratti C, Cecilia Rodríguez A
Source: Int J Cancer, 2012 Jul 1;131(1), p. 211-8.
EPub date: 2011 Aug 30.
Clustering of multiple human papillomavirus infections in women from a population-based study in Guanacaste, Costa Rica.
Authors: Vaccarella S, Franceschi S, Herrero R, Schiffman M, Rodriguez AC, Hildesheim A, Burk RD, Plummer M
Source: J Infect Dis, 2011 Aug 1;204(3), p. 385-90.
Sequence imputation of HPV16 genomes for genetic association studies.
Authors: Smith B, Chen Z, Reimers L, van Doorslaer K, Schiffman M, Desalle R, Herrero R, Yu K, Wacholder S, Wang T, Burk RD
Source: PLoS One, 2011;6(6), p. e21375.
EPub date: 2011 Jun 23.
Evolution and taxonomic classification of human papillomavirus 16 (HPV16)-related variant genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67.
Authors: Chen Z, Schiffman M, Herrero R, Desalle R, Anastos K, Segondy M, Sahasrabuddhe VV, Gravitt PE, Hsing AW, Burk RD
Source: PLoS One, 2011;6(5), p. e20183.
EPub date: 2011 May 27.
The age-specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: implications for screen-and-treat strategies.
Authors: Gage JC, Ajenifuja KO, Wentzensen NA, Adepiti AC, Eklund C, Reilly M, Hutchinson M, Wacholder S, Harford J, Soliman AS, Burk RD, Schiffman M
Source: Int J Cancer, 2012 May 1;130(9), p. 2111-7.
EPub date: 2011 Aug 5.
A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study.
Authors: Schiffman M, Glass AG, Wentzensen N, Rush BB, Castle PE, Scott DR, Buckland J, Sherman ME, Rydzak G, Kirk P, Lorincz AT, Wacholder S, Burk RD
Source: Cancer Epidemiol Biomarkers Prev, 2011 Jul;20(7), p. 1398-409.
EPub date: 2011 May 20.
Long-term persistence of prevalently detected human papillomavirus infections in the absence of detectable cervical precancer and cancer.
Authors: Castle PE, Rodríguez AC, Burk RD, Herrero R, Wacholder S, Hildesheim A, Morales J, Rydzak G, Schiffman M, Proyecto Epidemiológico Guanacaste Group
Source: J Infect Dis, 2011 Mar 15;203(6), p. 814-22.
Methylation of HPV16 genome CpG sites is associated with cervix precancer and cancer.
Authors: Sun C, Reimers LL, Burk RD
Source: Gynecol Oncol, 2011 Apr;121(1), p. 59-63.
Chlamydia trachomatis and risk of prevalent and incident cervical premalignancy in a population-based cohort.
Authors: Safaeian M, Quint K, Schiffman M, Rodriguez AC, Wacholder S, Herrero R, Hildesheim A, Viscidi RP, Quint W, Burk RD
Source: J Natl Cancer Inst, 2010 Dec 1;102(23), p. 1794-804.
EPub date: 2010 Nov 23.
Behavioral/lifestyle and immunologic factors associated with HPV infection among women older than 45 years.
Authors: González P, Hildesheim A, Rodríguez AC, Schiffman M, Porras C, Wacholder S, Piñeres AG, Pinto LA, Burk RD, Herrero R
Source: Cancer Epidemiol Biomarkers Prev, 2010 Dec;19(12), p. 3044-54.
EPub date: 2010 Oct 15.
Evolution of human papillomavirus carcinogenicity.
Authors: Van Doorslaer K, Burk RD
Source: Adv Virus Res, 2010;77, p. 41-62.
Degradation of p53 by human Alphapapillomavirus E6 proteins shows a stronger correlation with phylogeny than oncogenicity.
Authors: Fu L, Van Doorslaer K, Chen Z, Ristriani T, Masson M, Travé G, Burk RD
Source: PLoS One, 2010 Sep 17;5(9), p. null.
EPub date: 2010 Sep 17.
Alterations of T-cell surface markers in older women with persistent human papillomavirus infection.
Authors: Rodríguez AC, García-Piñeres AJ, Hildesheim A, Herrero R, Trivett M, Williams M, Atmella I, Ramírez M, Villegas M, Schiffman M, Burk R, Freer E, Bonilla J, Bratti C, Pinto LA
Source: Int J Cancer, 2011 Feb 1;128(3), p. 597-607.